– Enrollment in DURAVYU Phase 3 wet AMD clinical trials exceeding expectations with the LUGANO trial one-third enrolled and the LUCIA trial tracking ahead of schedule – – Full data for Phase 2 VERONA clinical trial of DURAVYU in DME expected in 1Q 2025 – – Appointed renowned retina specialist and industry leader Reginald J. Sanders, M.D., FASRS to Board of Directors – – Cash runway into 2027 beyond topline DURAVYU Phase 3 wet AMD data expected in 2026 – – Presenting at the 43rd Annual J.P. Morgan Healthcare ...